Cargando…

Evaluation of apremilast in chronic pruritus of unknown origin: A proof‐of‐concept, phase 2a, open‐label, single‐arm clinical trial

Detalles Bibliográficos
Autores principales:	Clark, Marie, Wang, Fang, Bodet, Nancy D., Kim, Brian S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178825/ https://www.ncbi.nlm.nih.gov/pubmed/32337373 http://dx.doi.org/10.1002/hsr2.154

Ejemplares similares

Interleukin-31 and Chronic Pruritus of Unknown Origin
por: Salao, Kanin, et al.
Publicado: (2020)

Efficacy of Apremilast in Patients with Prurigo Nodularis: A Proof-of-concept Study
por: TODBERG, Tanja, et al.
Publicado: (2020)

Truncal Pruritus of Unknown Origin May Be a Symptom of Diabetic Polyneuropathy
por: Yamaoka, Hiroyuki, et al.
Publicado: (2010)

Chronic Pruritus of Unknown Origin: Clinical Profile and Disease-Related Burden
por: PEREIRA, Manuel P., et al.
Publicado: (2021)

Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single-Arm Study
por: Okubo, Yukari, et al.
Publicado: (2022)

Open‐label, proof‐of‐concept study of brexanolone in the treatment of severe postpartum depression
por: Kanes, Stephen J., et al.
Publicado: (2017)

Structured physical exercise for bipolar depression: an open-label, proof-of concept study
por: Lafer, Beny, et al.
Publicado: (2023)

Efficacy of pregabalin for the treatment of chronic pruritus of unknown origin, assessed based on electric current perception threshold
por: Lee, JaeIn, et al.
Publicado: (2020)

Baricitinib rapidly and sustainably relieves a patient from chronic pruritus of unknown origin refractory to dupilumab
por: Buttgereit, Thomas, et al.
Publicado: (2021)

Modification of Apremilast from Pills to Aerosol a Future Concept
por: Zarogoulidis, Paul, et al.
Publicado: (2021)

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial
por: Fisher, Benjamin A, et al.
Publicado: (2022)

A feasibility and safety study of afamelanotide in acute stroke patients – an open label, proof of concept, phase iia clinical trial
por: Stanislaus, Vimal, et al.
Publicado: (2023)

Immuno-PET: Design options and clinical proof-of-concept
por: Lugat, Alexandre, et al.
Publicado: (2022)

An Open-Label, Randomized, Prospective, Comparative, Three-Arm Clinical Trial to Evaluate the Safety and Effectiveness of Apremilast with Three Different Titration Methods in Patients with Chronic Plaque Psoriasis in India
por: Viswanath, Vishalakshi, et al.
Publicado: (2022)

Autologous Bone Marrow Mononuclear Cell Therapy for Autism: An Open Label Proof of Concept Study
por: Sharma, Alok, et al.
Publicado: (2013)

Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study
por: Ozaki, Anna, et al.
Publicado: (2020)

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study
por: Connick, Peter, et al.
Publicado: (2012)

Original Research Work on Pruritus Ani
por: Murray, Dwight H.
Publicado: (1917)

ODP509 Proof-of-concept, Multicenter, Open-Label Phase 2a Study of Batoclimab in Active and Moderate-to-Severe Thyroid Eye Disease
por: Janes, Jonathan, et al.
Publicado: (2022)

Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study
por: Rajapaksa, Anushi E., et al.
Publicado: (2020)

Using Electronic Health Records to Derive Control Arms for Early Phase Single‐Arm Lung Cancer Trials: Proof‐of‐Concept in Randomized Controlled Trials
por: Carrigan, Gillis, et al.
Publicado: (2019)

Proof-of-concept single-arm trial of bevacizumab therapy for brain arteriovenous malformation
por: Muster, Rachel, et al.
Publicado: (2021)

Extended balloon labour induction: A single arm proof of concept trial
por: Matshitsa, Lorato, et al.
Publicado: (2023)

Lithium efficacy in bipolar depression with flexible dosing: A six-week, open-label, proof-of-concept study
por: MACHADO-VIEIRA, RODRIGO, et al.
Publicado: (2014)

An open-label proof-of-concept study of intrathecal autologous bone marrow mononuclear cell transplantation in intellectual disability
por: Sharma, Alok, et al.
Publicado: (2018)

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib
por: Boosman, René J., et al.
Publicado: (2022)

Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study
por: Jang, Jun Ho, et al.
Publicado: (2022)

Three-Day Icatibant on Top of Standard Care in Patients With Coronavirus Disease 2019 Pneumonia: A Randomized, Open-Label, Phase 2, Proof-of-Concept Trial
por: Malchair, Pierre, et al.
Publicado: (2023)

Evaluation of Artesunate-mefloquine as a Novel Alternative Treatment for Schistosomiasis in African Children (SchistoSAM): protocol of a proof-of-concept, open-label, two-arm, individually-randomised controlled trial
por: Roucher, Clémentine, et al.
Publicado: (2021)

Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes
por: Perkins, Bruce A., et al.
Publicado: (2015)

Pediatric psoriasis treated with apremilast
por: Smith, Rebecca L.
Publicado: (2016)

Erythrodermic Psoriasis Treated with Apremilast
por: Arcilla, John, et al.
Publicado: (2016)

Repigmentation of Tenacious Vitiligo on Apremilast
por: Huff, Sara B., et al.
Publicado: (2017)

Apremilast in Refractory Alopecia Areata
por: Estébanez, Andrea, et al.
Publicado: (2019)

Treatment of erythrodermic psoriasis with apremilast
por: Gioe, Olivia A., et al.
Publicado: (2021)

Mapping the Dielectric Properties of Unknown Targets by Using a Network of Microwave Sensors: A Proof-of-Concept †
por: Estatico, Claudio, et al.
Publicado: (2019)

Efficacy of a Moisturizer for Pruritus Accompanied With Asteatosis in Dialysis Patients: An Open-Label, Randomized, Exploratory Study
por: Yoshida, Yukie, et al.
Publicado: (2019)

Safety and Effectiveness of Difelikefalin in Patients With Moderate-to-Severe Pruritus Undergoing Hemodialysis: An Open-Label, Multicenter Study
por: Weiner, Daniel E., et al.
Publicado: (2022)

In vivo imaging of patients with chronic pruritus of unknown origin reveals partial sweat duct obstruction with partial itch resolution upon retinoid treatment
por: Lim, Shi Yu Derek, et al.
Publicado: (2023)

Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
por: McDade, Eric, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nhmlsmkqt35adtdms2paeja6h3